Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention

References

• Moussa ID, Colombo A. Antiplatelet therapy discontinuation following drug-eluting stent placement: Dangers, reasons, and management recommendations. Catheter Cardiovasc Interv 2009; 74: 1047–1054
   PubMed Web of Science ®Google Scholar
• Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, Han KH, Park SW, Yun SC, Lee SG, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362: 1374–1382
   PubMed Web of Science ®Google Scholar
• Tanzilli G, Greco C, Pelliccia F, Pasceri V, Barillà F, Paravati V, Pannitteri G, Gaudio C, Mangieri E. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study). Am J Cardiol 2009; 104: 1357–1361
   PubMed Web of Science ®Google Scholar
• Grines CL, Bonow RO, Casey DE, Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O’Gara P, Whitlow P. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007; 49: 734–739
   PubMed Web of Science ®Google Scholar
• Holmes DR, Jr, Kereiakes DJ, Laskey WK, Colombo A, Ellis SG, Henry TD, Popma JJ, Serruys PW, Kimura T, Williams DO, et al. Thrombosis and drug-eluting stents: An objective appraisal. J Am Coll Cardiol 2007; 50: 109–118
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. JACC 2011; 58: e44–e122
   Google Scholar
• Pamukçu B, Oflaz H, Nişanci Y. A current problem in atherothrombotic diseases-aspirin resistance: Definition, mechanisms, determination with laboratory tests and clinical implications. Anadolu Kardiyol Derg 2007; 7(Suppl. 2)20–26
   PubMedGoogle Scholar
• Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004; 328: 34
   Google Scholar
• McDonald J, Mathison DA, Stevenson DD. Aspirin intolerance in asthma-detection by challenge. J Allergy Clin Immunol 1972; 50: 198
   PubMed Web of Science ®Google Scholar
• Gollapudi RR, Teirstein PS, Stevenson DD, Simon RA. Aspirin sensitivity: Implications for patients with coronary artery disease. JAMA 2004; 292: 3017–3023
   PubMed Web of Science ®Google Scholar
• Ramanuja S, Breall JA, Kalaria VG. Approach to “aspirin allergy” in cardiovascular patients. Circulation 2004; 110: e1–e4
   Web of Science ®Google Scholar
• Rott D, Leibowitz D, Amit G, Zahger D, Weiss AT. Coronary artery stenting in patients treated by clopidogrel without aspirin. Int J Cardiol 2009; 133: 279–281
   PubMed Web of Science ®Google Scholar
• De Caterina R, Sicari R, Yan A, Bernini W, Giannessi D, Lazzerini G, Efthymiopoulos C, Strolin-Benedetti M. The d-enantiomer form of indobufen totally accounts for the anti-cyclooxygenase and antiplatelet activity ex vivo and for the increase in bleeding time by indobufen in man. Thromb Haemost 1992; 67: 258–263
   PubMed Web of Science ®Google Scholar
• De Caterina R, Giannessi D, Bernini W, Lazzerini G, Lavezzari M, Stragliotto E, Biagi G, Coccheri S. A prostacyclin-sparing effect of indobufen vs. aspirin. Thromb Haemost 1996; 75: 510–514
   PubMed Web of Science ®Google Scholar
• Cipollone F, Patrignani P, Greco A, Panara MR, Padovano R, Cuccurullo F, Patrono C, Rebuzzi AG, Liuzzo G, Quaranta G, et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 1997; 96: 1109–1116
   PubMed Web of Science ®Google Scholar
• Marzo A, Crestani S, Fumagalli I, Giusti A, Lowenthal DT. Endoscopic evaluation of the effects of indobufen and aspirin in healthy volunteers. Am J Ther 2004; 11: 98–102
   PubMedGoogle Scholar
• Cataldo G, Heiman F, Lavezzari M, Marubini E. Indobufen compared with aspirin and dipyridamole on graft patency after coronary artery bypass surgery: Results of a combined analysis. Coron Artery Dis 1998; 9: 217–222
   PubMed Web of Science ®Google Scholar
• Rajah SM, Nair U, Rees M, Saunders N, Walker D, Williams G, Critchley A, Beton D, Campbell C, Lawson RA. Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency one year after coronary artery bypass grafting. J Thorac Cardiovasc Surg 1994; 107: 1146–1153
   PubMed Web of Science ®Google Scholar
• Morocutti C, Amabile G, Fattapposta F, Nicolosi A, Matteoli S, Trappolini M, Cataldo G, Milanesi G, Lavezzari M, Pamparana F, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke 1997; 28: 1015–1021
   Google Scholar
• Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702–1708
   PubMed Web of Science ®Google Scholar
• Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 2004; 43: 979–984
   PubMed Web of Science ®Google Scholar
• Haubelt H, Anders C, Hellstern P. Can platelet function tests predict the clinical efficacy of aspirin?. Semin Thromb Hemost 2005; 31: 404–410
   PubMed Web of Science ®Google Scholar
• Frelinger AL, 3rd, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD. Association of cyclooxygenase-1-dependent and independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009; 120: 2586–2596
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, et al.; Academic Research Consortium. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007;115:2344–2351
   Google Scholar
• The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Eng J Med 1993; 329: 673–682
   PubMed Web of Science ®Google Scholar
• Tournoij E, Peters RJG, Langenberg M, Kanhai KJK, Moll FL. The prevalence of intolerance for low-dose acetylsalicylacid in the secondary prevention of atherothrombosis. Eur J Vasc Endovasc Surg 2009; 37: 597–603
   PubMed Web of Science ®Google Scholar
• Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther 1993; 54: 84–89
   PubMed Web of Science ®Google Scholar
• Silberman S, Neukirch-Stoop C, Steg PG. Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol 2005; 95: 509–510
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, et al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–2015
   Google Scholar
• Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–1057
   PubMed Web of Science ®Google Scholar
• Sibbing D, Morath T, Braun S, Stegherr J, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010; 103: 151–159
   PubMed Web of Science ®Google Scholar
• Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849–856
   PubMed Web of Science ®Google Scholar
• Latib A, Ielasi A, Ferri L, Chieffo A, Godino C, Carlino M, Montorfano M, Colombo A, Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: A proposed alternative regimen. Int J Cardiol. 2011 Oct 1 [Epub ahead of print]
   Google Scholar
• Rebuzzi AG, Natale A, Bianchi C, Mariello F, Coppola E, Ciabattoni G. Effects of indobufen on platelet thromboxane B2 production in patients with myocardial infarction. Eur J Clin Pharmacol 1990; 39: 99–100
   PubMed Web of Science ®Google Scholar
• Mannucci L, Maderna P, Colli S, Lavezzari M, Sirtori CR, Tremoli E. Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic risk. Thromb Res 1987; 48: 417–426
   PubMed Web of Science ®Google Scholar
• Davì G, Patrono C, Catalano I, Custro N, Giammarresi C, Ganci A, Cosentino F, Notarbartolo A. Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus. Arterioscler Thromb Vasc Biol 1993; 13: 1346–1349
   Google Scholar